These results are in keeping with phase 2 data in patients with NASH, where licogliflozin, a dual SGLT1/2 inhibitor, potently reduced liver enzymes.13 The highest dose, 150 mg, also reduced liver fat. Here, SLC5A1 is linked to metabolic dysfunction-associated steatohepatitis.